TScan Therapeutics
- Company typePublic
- Founded2018
- HeadquartersWaltham, United States
- Headcount101–250
- GTM typeB2B
- OfferingServices
TScan Therapeutics firmographics
Firmographics- Name
- TScan Therapeutics
- Legal name
- TScan Therapeutics, Inc.
- Website
- https://tscan.com
- Company type
- Public
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Ownership category
- akta.pro rank
TScan Therapeutics industry classification
Industry- Product category
- Cancer Immunotherapy
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- CAR-T & TCR-T Therapies (HLAAABAC)
- akta.pro secondary industry
- Bone Marrow & Stem Cell Transplant (BMT/HSCT) (HLAKAFAI)
Keywords
Where TScan Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Waltham
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
TScan Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Collaboration Revenue: Revenue from multi-year collaboration agreement with Amgen for TargetScan platform utilization in Crohn's disease research. Revenue of $1.0M in Q1 2026, down from $2.2M in Q1 2025 due to timing of research activities.
- Future Product Revenue: Pre-revenue stage company. Anticipated future revenue from commercialization of TCR-T therapy candidates, primarily TSC-101 for AML and MDS.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
TScan Therapeutics product offering
Product offeringCore offering
TScan Therapeutics is a clinical-stage biotechnology company developing allogeneic, donor-derived T cell receptor-engineered T cell (TCR-T) therapies to treat patients with hematologic malignancies and solid tumors. Its lead candidate TSC-101 targets the HA-2 antigen for HLA-A*02:01-positive AML and MDS patients undergoing allogeneic hematopoietic cell transplantation to eliminate residual disease and prevent relapse, supported by the proprietary TargetScan genome-wide TCR epitope discovery platform.
Product overview
TScan Therapeutics is a clinical-stage biotechnology company developing a pipeline of T cell receptor-engineered T cell (TCR-T) therapies for cancer treatment. The company's core product is TSC-101, an allogeneic TCR-T therapy targeting the HA-2 antigen for AML and MDS patients undergoing transplantation. Additional pipeline products include TSC-102, targeting CD45 for multiple HLA types. The technology foundation is the TargetScan discovery platform, which enables genome-wide identification of T cell epitopes. The company is also developing an in vivo engineering platform for off-the-shelf, multiplexed TCR-T therapies targeting solid tumors. TScan operates primarily in hematologic malignancies while maintaining programs in solid tumors and autoimmunity.
Differentiator
Problem solved
Functional benefit
Products and services
- TSC-101 Lead allogeneic, donor-derived TCR-T therapy candidate targeting the HA-2 antigen for HLA-A*02:01-positive patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) undergoing allogeneic hematopoietic cell transplantation; designed to eliminate residual disease and prevent relapse.
- TSC-102 Allogeneic, donor-derived TCR-T therapy candidates targeting epitopes derived from CD45 for patients with HLA types A*01:01, A*03:01, and A*24:02; designed to eliminate residual cancer cells and prevent relapse in patients undergoing HCT for hematologic malignancies and to expand the addressable patient population beyond HLA-A*02:01.
- TargetScan Discovery Platform Proprietary genome-wide target discovery platform that enables rapid identification of peptide antigen targets of T cell receptors; used internally to discover TCR/target pairs for TScan's pipeline and licensed to partners (e.g., Amgen) for T cell antigen identification in indications such as Crohn's disease.
- In Vivo-Engineered TCR-T Platform An in vivo engineering platform for delivering off-the-shelf, multiplexed TCR-T therapy for solid tumors, intended as a cost-efficient approach to treat heterogeneous solid tumor malignancies.
Quantifiable outcome
- 93% response rate in Phase 1 ALLOHA trial Cohort C
- +4 more outcomes
Companies that use TScan Therapeutics
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
TScan Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
TScan Therapeutics partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- CellarescoreAgreement to evaluate automated clinical manufacturing of TSC-101 using Cellares' fully automated Cell Shuttle and Cell Q platforms. Aims to reduce process variability and enable scalable, cost-efficient production as TScan prepares for pivotal trial expected Q2 2026.
- AmgencoreMulti-year collaboration initiated May 2023 leveraging TScan's TargetScan platform to identify antigens recognized by T cells in Crohn's disease patients. Amgen retains all global development and commercial rights to discovered targets. TScan receives research funding and potential milestones.
Scale indicators8 records
Recent moves3 records
TScan Therapeutics competitors and assessment
Company assessmentDirect peers
- Adaptimmune Therapeutics: Clinical-stage biotech developing SPEAR T-cell receptor (TCR-T) therapies for solid tumors. Adaptimmune is the most directly comparable TCR-T competitor, with an FDA-approved product (TECELRA) and overlapping platform approach to engineered T-cell therapy.
- Immatics: Clinical-stage biotech developing TCR-based immunotherapies for solid tumors using a proprietary target discovery platform (XPRESIDENT). Immatics is highly comparable given its TCR-T focus and discovery-platform business model similar to TScan's TargetScan.
- Iovance Biotherapeutics: Commercial-stage cell therapy company with FDA-approved lifileucel (Amtagvi) for solid tumors. Iovance is a direct peer in autologous cell therapy manufacturing and oncology commercialization, with overlapping clinical and operational challenges to TScan's TCR-T approach.
- Allogene Therapeutics: Clinical-stage biotech developing allogeneic (off-the-shelf) CAR-T cell therapies for hematologic and solid tumors. Allogene's allogeneic platform addresses the same scalability and HLA-matching challenges TScan faces with its donor-derived TCR-T approach.
- Precision BioSciences: Clinical-stage biotech developing allogeneic CAR-T therapies using its ARCUS gene editing platform. Precision is a peer in engineered cell therapy development with similar allogeneic manufacturing complexity and oncology focus.
- Caribou Biosciences: Clinical-stage biotech developing allogeneic CAR-T cell therapies using CRISPR-based gene editing. Caribou is a peer in allogeneic cell therapy development targeting hematologic malignancies with comparable manufacturing and clinical execution requirements.
- Cellectis: Clinical-stage biotech developing gene-edited allogeneic CAR-T cell therapies (UCART platform). Cellectis is a peer in allogeneic engineered cell therapy with similar TCR/CAR hybrid approaches and TALEN-based gene editing for cell therapy manufacturing.
Broad incumbents
- CRISPR Therapeutics: Commercial-stage gene editing company with FDA-approved Casgevy (exa-cel) for sickle cell disease and beta-thalassemia. CRISPR Therapeutics is a broad incumbent in gene-edited cell therapy with established manufacturing infrastructure and overlapping cell therapy talent pool (TScan CMO previously worked there).
Emerging players
- Fate Therapeutics: Clinical-stage biotech developing iPSC-derived off-the-shelf NK and T-cell therapies. Fate represents an emerging modality that could compete with TScan's donor-derived TCR-T if iPSC-derived approaches achieve commercial viability.
- Vor Biopharma: Clinical-stage biotech focused on engineered hematopoietic cell transplants for AML and other hematologic malignancies. Vor Biopharma addresses the same post-transplant relapse setting that TScan targets with TSC-101, representing an alternative modality competing for the same clinical opportunity.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
TScan Therapeutics social profiles
Digital presenceTScan Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
TScan Therapeutics leadership team
Management profileNumber of profiles
Profiles15 records
TScan Therapeutics funding detail
Funding detailFunding overview
Funding rounds8 records
Investors14 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
TScan Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about TScan Therapeutics
What does TScan Therapeutics do?
TScan Therapeutics is a clinical-stage biotechnology company developing allogeneic, donor-derived T cell receptor-engineered T cell (TCR-T) therapies to treat patients with hematologic malignancies and solid tumors. Its lead candidate TSC-101 targets the HA-2 antigen for HLA-A*02:01-positive AML and MDS patients undergoing allogeneic hematopoietic cell transplantation to eliminate residual disease and prevent relapse, supported by the proprietary TargetScan genome-wide TCR epitope discovery platform.
Is TScan Therapeutics a public or private company?
TScan Therapeutics is a public company. It is classified as public and is currently operating.
When was TScan Therapeutics founded?
TScan Therapeutics was founded in 2018. It employs 101 to 250 people.
Where is TScan Therapeutics based?
TScan Therapeutics is headquartered in Waltham, United States, in the North America region.
How does TScan Therapeutics make money?
Two revenue lines are on record. Collaboration Revenue is the primary driver. The others are future Product Revenue.
Who are TScan Therapeutics's main competitors?
Direct peers on record are Adaptimmune Therapeutics, Immatics, Iovance Biotherapeutics, Allogene Therapeutics, Precision BioSciences, Caribou Biosciences and Cellectis. CRISPR Therapeutics is listed as a broad incumbent. Emerging players are Fate Therapeutics and Vor Biopharma.
Does TScan Therapeutics have an API?
No public API is recorded for TScan Therapeutics.
What industry is TScan Therapeutics in?
TScan Therapeutics's product category is Cancer Immunotherapy. Its primary akta.pro industry code is HLAAABAC, CAR-T & TCR-T Therapies, with a secondary code of HLAKAFAI, Bone Marrow & Stem Cell Transplant (BMT/HSCT). Its NAICS code is 325414 and its SIC code is 2836.